We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biomarker Discovered for Pregnancy-Related Heart Disease

By LabMedica International staff writers
Posted on 16 May 2013
A molecule has been identified that can serve as a biomarker for peripartum cardiomyopathy that occurs in pregnant women during the last month or in the months following their pregnancy.

The molecule is a micro-ribonucleic acid (miRNA) which is induced by the nursing hormone prolactin and detection in the blood, protected from endogenous ribonuclease (RNase) activity by exosomes, has emerged as a promising diagnostic tool.

Scientists at the University of Liege (Belgium) obtained plasma samples from 38 patients with peripartum cardiomyopathy (PPCM) at their first presentation and from18 healthy nursing women, from five age-matched healthy controls, from 30 patients with heart failure due to dilated cardiomyopathy (DCM), and from patients with PPCM receiving bromocriptine. More...


The investigators found the expression miRNA miR-146a was induced by the nursing hormone prolactin. MiR-146a expression promoted vascular damage and was increased in a mouse model of PPCM. Conversely, loss of miR-146a in mice prevented PPCM. Plasma levels of miR-146a were significantly higher in patients with acute PPCM compared with healthy postpartum controls. Levels of miR-146a were not significantly different between healthy postpartum controls and healthy nonpregnant women. Compared with 30 patients with a similar degree of heart failure due to DCM and with no history of PPCM, miR-146a levels were significantly higher in the PPCM group.

The results of this study indicate that miR-146a mediates antiangiogenic effects of 16-kDa N-terminal prolactin fragment (16K PRL) in endothelial cells and the slowing of metabolism in cardiomyocytes. In addition, this microRNA may serve as a highly specific blood biomarker useful for diagnosis and risk stratification of patients with peripartum heart failure and appears to be a specific biomarker of PPCM. The study was published on April 24, 2013, in the Journal of Clinical Investigation.

Related Links:

University of Liege




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.